Isamu Okamoto1, Satoshi Morita2, Naoki Tashiro3, Fumio Imamura4, Akira Inoue5, Takashi Seto6, Nobuyuki Yamamoto7, Yuichiro Ohe8, Kazuhiko Nakagawa9, Masahiro Fukuoka10. 1. Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Electronic address: okamotoi@kokyu.med.kyushu-u.ac.jp. 2. Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. Electronic address: smorita@kuhp.kyoto-u.ac.jp. 3. AstraZeneca K. K., Grand Front Osaka Tower B, 3-1 Ofuka-cho, Kita-ku, Osaka, 530-0011, Japan. Electronic address: Naoki.Tashiro@astrazeneca.com. 4. Department of Thoracic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan. Electronic address: imamura-fu@mc.pref.osaka.jp. 5. Department of Palliative Medicine, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. Electronic address: akira.inoue.b2@tohoku.ac.jp. 6. Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan. Electronic address: tseto@nk-cc.go.jp. 7. Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. Electronic address: nbyamamo@wakayama-med.ac.jp. 8. Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: yohe@ncc.go.jp. 9. Department of Medical Oncology, Kindai University, Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, 589-8511, Japan. Electronic address: nakagawa@med.kindai.ac.jp. 10. Department of Medical Oncology, Izumi Municipal Hospital, 4-10-10 Fuchu, Izumi, 594-0071, Japan. Electronic address: fukuoka@izumi-hp.com.
Abstract
OBJECTIVES: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. MATERIALS AND METHODS: Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. RESULTS: The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2% and 21.5%, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. CONCLUSIONS: This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.
OBJECTIVES: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. MATERIALS AND METHODS: Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. RESULTS: The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2% and 21.5%, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. CONCLUSIONS: This large, long-term analysis of EGFR mutation-positive NSCLCpatients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLCpatients treated with the latest available agents, including immunotherapies.
Authors: Shemra Rizzo; Sarah Waliany; Marius Rene Garmhausen; Navdeep Pal; Ruishan Liu; Zhi Huang; Nayan Chaudhary; Lisa Wang; Chris Harbron; Joel Neal; Ryan Copping; James Zou Journal: Nat Med Date: 2022-06-30 Impact factor: 87.241
Authors: Nayra S Amaral; Vivian Resende; José Sebastião Dos Santos; Luiz Felipe Lima; Debora C Moraes; Eitan Friedman; Luiz DE Marco; Luciana Bastos-Rodrigues Journal: In Vivo Date: 2018 Nov-Dec Impact factor: 2.155
Authors: Jo Morrison; Clemens Thoma; Richard J Goodall; Thomas J Lyons; Kezia Gaitskell; Alison J Wiggans; Andrew Bryant Journal: Cochrane Database Syst Rev Date: 2018-10-16